Novel MRI Biomarkers for Monitoring Disease Progression in ALS

Status: Recruiting
Location: See all (9) locations...
Study Type: Observational
SUMMARY

Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a biomarker) by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS. Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Patients with a suspected or confirmed diagnosis as described in Study Populations

• For those with a diagnosis of ALS, patients will be considered with an El Escorial classification of suspected, possible, probable, probable lab-supported, and definite ALS.

• Patients 18 years of age or older

• Healthy controls over the age of 40.

• Be able to lie in an MRI machine for approximately 60 minutes

Locations
United States
Florida
University of Miami
RECRUITING
Miami
Utah
University of Utah
RECRUITING
Salt Lake City
Other Locations
Canada
University of Calgary / Heritage Medical Research Clinic
RECRUITING
Calgary
University of Alberta
RECRUITING
Edmonton
Western University / London Health Sciences Centre
WITHDRAWN
London
McGill University / Montreal Neurological Institute and Hospital
RECRUITING
Montreal
Laval University
RECRUITING
Québec
University of Toronto / Sunnybrook Health Sciences Centre
RECRUITING
Toronto
University of British Columbia / GF Strong Rehab Centre
WITHDRAWN
Vancouver
Contact Information
Primary
Sara Moradipoor, MSc
moradipo@ualberta.ca
780-248-1805
Time Frame
Start Date: 2016-10
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 700
Treatments
Patients
ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
Controls
Healthy controls who are age and gender matched to patients.
Sponsors
Collaborators: University of Miami, McGill University, University of British Columbia, University of Toronto, University of Utah, University of Calgary, Western University, Canada, Laval University
Leads: University of Alberta

This content was sourced from clinicaltrials.gov